The PharmGKB review of the Sorafenib
pathways has been published in the journal Pharmacogenetics and Genomics. Sorafenib (NEXAVAR®,
BAY43-9006) is an oral anti-cancer drug approved for the treatment of metastatic
or advanced liver, kidney, and thyroid cancers. Although many new
targeted therapies have been tested over the past decade, sorafenib remains the
standard of care for these diseases due to its modest efficacy and acceptable
tolerability. In this review, we discuss the pharmacokinetic and
pharmacodynamic properties of sorafenib and highlight genetic variations that
may contribute to the diverse pharmacological responses to sorafenib.
Find out more...
View interactive pathways on PharmGKB:Sorafenib Pharmacokinetics Pathway
Sorafenib Pharmacodynamics Pathway
Read our new publication:
Pharmacogenet
Genomics. 2017 Mar 30
Gong Li, Giacomini Marilyn M, Giacomini Craig, Maitland
Michael L, Altman Russ B, Klein Teri E
PMID: 28362716
View all pathways on PharmGKB.
No comments:
Post a Comment